CliffBio
biologic

Imdelltra

tarlatamab-dlle

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameImdelltra
Active ingredienttarlatamab-dlle
Strength10MG
Dosage formInjection
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.